News for Eledon Pharmaceuticals, Inc. (ELDN)

On June 30, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,600,289 shares of Eledon Pharmaceuticals I

Eledon Pharmaceuticals is poised to revolutionize kidney transplant care with tegoprubart, targeting a $6B market. Read why ELDN stock is a strong buy.

We came across a bullish thesis on Materialise NV (MTLS) on Substack by Industrial Tech Stock Analyst. In this article, we will summarize the bulls’ thesis on MTLS. Materialise NV (MTLS)’s share was trading at $5.29 as of April 24th. MTLS’s trailing P/E was 20.31 according to Yahoo Finance. Materialise (MTLS) delivered a strong 1Q25 performance, with […]

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massach

**media[572463]**

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial su

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (”œEledon”) ( ELDN) today announced that Steve Perrin, Ph.D., Chief Scienti

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) made a significant move by acquiring an additional 773,553 shares of Eledon Pharmaceuticals Inc

Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Inves

**media[527606]**

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more about ELDN stock here.

Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results i

Overview of the Recent Transaction On October 29, 2024, RA Capital Management, L.P. made a significant new investment in the biotechnology sector by purchasing

Eledon Pharmaceuticals reports positive Phase 1b data for tegoprubart in kidney transplants. Learn why ELDN stock could benefit from upcoming trial results.

**media[450050]**

Amyotrophic lateral sclerosis treatment industry is projected to witness a CAGR of 5.5% during the period 2024-2032. This growth can be attributed to the...

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants...

Stocks Analysis by Ismael De La Cruz covering: Blink Charging Co, Eledon Pharmaceuticals Inc, Nio Inc Class A ADR, Acumen Pharmaceuticals Inc. Read Ismael De La Cruz's latest article on Investing.com

The growing geriatric population, rising burden of skin diseases, and rising R&D on novel biopharmaceuticals. AbbVie Inc., Allergan, Merck & Co., Inc., and...